Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
March 25, 2020 at 08:35 am EDT
Share
DGAP Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
25.03.2020 / 13:30
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
Evotec SE
Street:
Manfred Eigen Campus / Essener Bogen 7
Postal code:
22419
City:
Hamburg Germany
Legal Entity Identifier (LEI):
529900F9KI6OYITO9B12
2. Reason for notification
Acquisition/disposal of shares with voting rights
X
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Legal entity: The Goldman Sachs Group, Inc. City of registered office, country: Wilmington, DE, United States of America (USA)
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
5. Date on which threshold was crossed or reached:
20 March 2020
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
0.10 %
4.68 %
4.78 %
151228427
Previous notification
0.21 %
5.45 %
5.67 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE0005664809
0
157215
0 %
0.10 %
US30050E1055
0
516
0 %
0.0003 %
Total
157731
0.10 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
Right To Recall
Open
3432776
2.27 %
Total
3432776
2.27 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
Swap
31.12.2030
Cash
2048628
1.35 %
Call Warrant
31.12.2030
Cash
1425215
0.94 %
Put Warrant
31.12.2030
Cash
171142
0.11 %
Total
3644986
2.41 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
The Goldman Sachs Group, Inc.
%
%
%
GSAM Holdings LLC
%
%
%
Goldman Sachs Asset Management, L.P.
%
%
%
-
%
%
%
The Goldman Sachs Group, Inc.
%
%
%
Goldman, Sachs & Co. Wertpapier GmbH
%
%
%
-
%
%
%
The Goldman Sachs Group, Inc.
%
%
%
Goldman Sachs & Co. LLC
%
%
%
-
%
%
%
The Goldman Sachs Group, Inc.
%
%
%
IMD Holdings LLC
%
%
%
United Capital Financial Partners, Inc.
%
%
%
United Capital Financial Advisers, LLC
%
%
%
-
%
%
%
The Goldman Sachs Group, Inc.
%
%
%
Goldman Sachs (UK) L.L.C.
%
%
%
Goldman Sachs Group UK Limited
%
%
%
Goldman Sachs International
%
%
%
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
Date
24 March 2020
25.03.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.